Danaher is tapping the M&A well yet again. But we might have had enough

Shares of Danaher Corporation dropped following the announcement of its planned acquisition of Masimo, a prominent medical technology company, as investors reacted to the latest in a series of mergers and acquisitions by the diversified science and technology leader. The deal represents Danaher's continued strategy of growth through acquisition, following a pattern that has defined the company's expansion for years. Masimo, known for its innovative monitoring technologies, particularly in pulse oximetry, brings valuable intellectual property and market position that would strengthen Danaher's portfolio in the healthcare sector. Market analysts suggest the decline in Danaher's stock price may reflect concerns about the premium being paid for Masimo or skepticism about the integration challenges ahead. The acquisition comes at a time when Danaher has been actively pursuing M&A opportunities, with investors potentially questioning whether the company's acquisition strategy has reached its saturation point. Some industry observers note that this latest move follows a string of previous acquisitions by Danaher, raising questions about whether the company's growth through consolidation is sustainable or if it has 'had enough' as the article's title suggests. The medtech sector has seen significant consolidation in recent years, with larger companies acquiring innovative smaller firms to enhance their product offerings and market presence. Danaher's acquisition of Masimo, if completed, would further concentrate the market, potentially reducing competition but also bringing together complementary technologies.